SCORTEN overestimates mortality in the setting of a standardized treatment protocol

Journal of Burn Care and Research

Volumn 27, Issue 3, 2006, Pages 270-275

  Imahara, Scott D ^a   Holmes IV, James H ^a   Heimbach, David M ^a   Engrav, Loren E ^a   Honari, Shari ^a   Klein, Matthew B ^a   Gibran, Nicole S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL PATHWAY; CLINICAL PROTOCOL; DEATH; DISEASE SEVERITY; ENTERIC FEEDING; EXFOLIATIVE DERMATITIS; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT MONITORING; PROBABILITY; RARE DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SCORTEN SCORE; SKIN PROTECTION; STANDARDIZATION; TOXIC EPIDERMAL NECROLYSIS; TREATMENT INDICATION; TREATMENT OUTCOME; XENOGRAFT;

ADULT; AGE FACTORS; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTICONVULSANTS; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STEROIDS; SURVIVAL ANALYSIS;

EID: 33745659394     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/01.BCR.0000216532.71360.9B     Document Type: Article

References (27)

1. Chan HL. Observations on drug-induced toxic epidermal necrolysis in Singapore. J Am Acad Dermatol 1984;10:973-8.
2. Roujeau JC, Guillaume JC, Fabre JP, Penso D, Flechet ML, Girre JP. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990;126:37-42.
3. Schopf E, Stuhmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol 1991;127:839-42.
4. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990;126:43-7.
5. Stevens A, Johnson F. A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children. Am J Dis Child 1922;24:526.
6. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956;68:355-61.
7. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7.
8. Palmieri TL, Greenhalgh DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 2002;23:87-96.
9. Becker DS. Toxic epidermal necrolysis. Lancet 1998;351:1417-20.
10. Schulz JT, Sheridan RL, Ryan CM, MacKool B, Tompkins RG. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000;21:199-204.
11. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53.
12. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol 2004;140:890-2.
13. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 2004;25:81-8.
14. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003;139:33-6.
15. Heimbach DM, Engrav LH, Marvin JA, Harnar TJ, Grube BJ. Toxic epidermal necrolysis. A step forward in treatment. JAMA 1987;257:2171-5.
16. Marvin JA, Heimbach DM, Engrav LH, Harnar TJ. Improved treatment of the Stevens-Johnson syndrome. Arch Surg 1984;119:601-5.
17. Honari S, Gibran NS, Heimbach DM, et al. Toxic epidermal necrolysis (TEN) in elderly patients. J Burn Care Rehabil 2001;22:132-5.
18. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience Arch Dermatol. 2003;139:39-43.
19. Liddell FD. Simple exact analysis of the standardised mortality ratio. J Epidemiol Community Health 1984;38:85-8.
20. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000;136:323-7.
21. Bradley T, Brown RE, Kucan JO, Smoot 3rd EC, Hussmann J. Toxic epidermal necrolysis: a review and report of the successful use of Biobrane for early wound coverage. Ann Plast Surg 1995;35:124-32.
22. Spies M, Sanford AP, Aili Low, JF, Wolf SE, Herndon DN. Treatment of extensive toxic epidermal necrolysis in children. Pediatrics 2001;108:1162-8.
23. Pianigiani E, Ierardi F, Taddeucci P, et al. Skin allograft in the treatment of toxic epidermal necrolysis (TEN). Dermatol Surg 2002;28:1173-6.
24. Birchall N, Langdon R, Cuono C, McGuire J. Toxic epidermal necrolysis: an approach to management using cryopreserved allograft skin. J Am Acad Dermatol. 1987;16:368-72.
25. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-3.
26. Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139:26-32.
27. Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004;25:246-55.